Moderna, a leading biotechnology company, has recently announced a groundbreaking partnership with OpenAI to ramp up the development of life-saving treatments. By deploying ChatGPT Enterprise to their vast workforce, Moderna has seen a surge in productivity and innovation within their organization.
One of the most impressive outcomes of this collaboration is the creation of customized versions of ChatGPT, including the pilot Dose ID GPT. This specialized tool utilizes advanced data analysis to evaluate and verify the optimal vaccine dose chosen by Moderna’s clinical study team.
The integration of AI technology like ChatGPT has revolutionized the way Moderna operates, enabling them to streamline processes, make data-driven decisions, and ultimately accelerate the development of life-saving treatments.
To learn more about Moderna’s transformation with ChatGPT, visit their customer stories page on the OpenAI website. This partnership highlights the power of combining cutting-edge technology with innovative minds to bring about positive change in the world of biotechnology.
Watch the video by OpenAI
Video “Moderna partners with OpenAI to accelerate the development of life-saving treatments” was uploaded on 04/24/2024 to Youtube Channel OpenAI